Catheter Precision (NYSEAMERICAN:VTAK – Get Free Report) is anticipated to release its results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of ($13.30) per share and revenue of $2.80 million for the quarter.
Catheter Precision Stock Performance
Shares of VTAK stock opened at $0.15 on Thursday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.18 and a current ratio of 0.19. Catheter Precision has a 52-week low of $0.13 and a 52-week high of $3.20. The company has a market capitalization of $2.17 million, a PE ratio of -0.02 and a beta of -0.99. The business’s fifty day moving average is $0.99 and its 200 day moving average is $8.10.
Catheter Precision Company Profile
Catheter Precision, Inc is a medical device company focused on developing technologies for cardiac electrophysiology, a field involving the diagnosis and treatment of heart-rhythm disorders. Its products are designed to support physicians during procedures used to evaluate and treat cardiac arrhythmias, including ventricular tachycardia and other irregular heart rhythms.
The company’s product portfolio includes the VIVO system, a noninvasive 3D cardiac mapping and navigation platform intended to help clinicians identify the origin of ventricular arrhythmias and plan catheter-ablation procedures.
Featured Stories
- Five stocks we like better than Catheter Precision
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Catheter Precision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catheter Precision and related companies with MarketBeat.com's FREE daily email newsletter.
